



ADVANCED PROSTATE CANCER  
CONSENSUS CONFERENCE  
25-27 April, 2024 - Lugano, Switzerland

# PROGRAMME



# APCCC 2024 Final programme



# Thursday, April 25

09:00-09:15

## Opening

APCCC 2024	Silke Gillessen Aurelius Omlin	7 min
What is important from a patient's perspective?	David Matheson	8 min

09:15-11:35

## Session 1

High-risk and locally advanced prostate cancer	Chairs: Neha Vapiwala and Neal Shore	140 min
High-risk and locally advanced prostate cancer in the context of current diagnostic and therapeutic options – which is the ideal definition to use for clinical practice?	Martin E. Gleave	10 min
Is digital rectal examination for definition of local T-stage still appropriate in the time MRI and next-generation imaging?	Declan G. Murphy	10 min
Regional lymph node staging for high-risk and locally advanced prostate cancer – What should be the standard?	Jochen Walz	10 min
Genomic classifiers and artificial intelligence (AI) as predictors for treatment benefit	Daniel E. Spratt	10 min
Q&A (15 min)		
Radiation therapy schedules and fields for high-risk and locally advanced prostate cancer	Neha Vapiwala	10 min
Debate: How to best manage a fit patient with high-risk localised and locally advanced prostate cancer?		
Surgery as radical local treatment (as part of a multimodality approach)	Alberto Briganti	10 min
Radiation therapy as radical local treatment (as part of a multimodality approach)	Piet Ost	10 min
How to select patients for adjuvant therapy after radical prostatectomy and how to treat them?	Jason A. Efstathiou	10 min
Q&A (15 min)		
Discussion of APCCC 2024 voting results (30 min)		

11:35-12:05

## Coffee break

# Thursday, April 25

12:05–13:00

## Session 2 - PART 1

Treatment for biochemical recurrence/PSA persistence	Chairs: Thomas Zilli and Derya Tilki	55 min
How to manage patients with PSA persistence following radical prostatectomy?	Derya Tilki	10 min
How to select patients with biochemical relapse in whom salvage radiation therapy can be postponed?	Barbara A. Jereczek-Fossa	10 min
Which patients with high-risk first BCR after radical prostatectomy are candidates for systemic therapy alone without local salvage RT?	Bertrand F. Tombal	10 min
In patients who receive salvage radiation therapy for BCR, who needs additional systemic therapy, what and for how long?	Daniel E. Spratt	10 min

Q&A (15 min)

13:00–14:00

## Lunch

14:00–15:15

## Session 2 - PART 2

Treatment for biochemical recurrence/PSA persistence	Chairs: Jason A. Efstathiou and Barbara A. Jereczek-Fossa	75 min
In patients with BCR and positive lesion(s) in the pelvis – stereotactic or whole pelvis RT?	Paul L. Nguyen	10 min
Are some patients with BCR (after RT and/or RP) candidates for AR antagonist monotherapy and how to manage the systemic therapy?	Neal Shore	10 min
Second BCR (without correlate on NGI) after salvage radiation and/or after metastases directed therapy: How to manage these patients?	Ray McDermott	10 min

Q&A (15 min)

Discussion of APCCC 2024 voting results (30 min)

15:15–15:45

## Coffee break

15:45– 17:15

## Session 3 - PART 1

Management of metastatic hormone-sensitive prostate cancer (mHSPC)	Chairs: Sandy Srinivas and Bertrand F. Tombal	90 min
Introduction to mHSPC – what are relevant prognostic/predictive factors for management of patients?	Matthew R. Smith	10 min



# Thursday, April 25

Synchronous low-volume mHSPC – In which patients do you recommend combination systemic therapy plus local treatment of the primary and in which patients is ADT alone plus RT enough?	Robert J. Jones	10 min
In which patients with synchronous low-volume mHSPC do you recommend “total therapy”?	Oliver A. Sartor	10 min
Should the primary be treated in synchronous high-volume mHSPC	Sandy Srinivas	10 min
Which patients with mHSPC should get triplet systemic therapy: ADT plus docetaxel plus ARPI?	Nicholas D. James	10 min
In which patients with metachronous low-volume mHSPC do you recommend “total therapy”?	Thomas Zilli	10 min
Ideal monitoring of patients with mHSPC – what is recommended in daily clinical practice?	Michael J. Morris	10 min

Q&A (20 min)

17:15

End of Day 1

from 17:30

Networking reception



# Friday, April 26

08:30-08:50

## Extra session

Movember Session	Chair: Daniel J. George	20 min
Update on IRONMAN Project	Alicia K. Morgans	10 min

Discussion (10 min)

09:00-10:45

## Session 3 - PART 2

Management of metastatic hormone-sensitive prostate cancer (mHSPC)	Chairs: Mary-Ellen Taplin and Karim Fizazi	105 min
Which patients with mHSPC can be offered a treatment break (de-escalation strategies) and how to manage the break?	Bertrand F. Tombal	10 min
Escalation strategies in patients with mHSPC and an unfavourable PSA decline – is more better?	Mary-Ellen Taplin	10 min
How to manage patients with low-volume on conventional and high-volume on NHI	Dana Rathkopf	10 min
Management of patients with mHSPC and early progression on combination therapy	Christopher J. Sweeney	10 min
Management of frail patients with mHSPC	Maria De Santis	10 min
Future changes in the setting of mHSPC	Gerhardt Attard	10 min

Q&A (15 min)

Discussion of APCCC 2024 voting results (30 min)

10:45-11:15

## Coffee break

11:15-13:00

## Session 4

Identification, assessment and management of side effects of systemic therapies	Chairs: Lisa G. Horvath and Christopher J. Sweeney	105 min
Cardiovascular complications in advanced prostate cancer – how to prevent them and how to monitor patients?	Thomas Suter	10 min
How to select ADT and ARPI based on CV risk profile	Charles J. Ryan	10 min

# Friday, April 26

Importance of bone protection	Noel Clarke	10 min
Gynecomastia – How to assess and treat?	Lisa G. Horvath	10 min
Hot flushes – How can we help our patients?	Anthony Joshua	10 min
Testosterone recovery after stopping ADT – Who is at risk for long-term non-recovery?	Pierre Blanchard	10 min

Q&A (15 min)

Discussion of APCCC 2024 voting results (30 min)

13:00–14:15

Lunch

14:15–16:00

Session 5

Management of metastatic CRPC	Chairs: Elena Castro and Ian D. Davis	105 min
When to do tumour genomic profiling in advanced prostate cancer and what?	Niven Mehra	10 min
Ideal sequence after ADT alone or ADT plus ARPI for mHSPC	Ian D. Davis	10 min
Ideal sequence after ADT plus ARPI plus docetaxel for mHSPC	Karim Fizazi	10 min
Best use of PARP inhibitors in mCRPC	Joaquin Mateo	10 min
PARP inhibition dissected – in which DNA repair gene alterations works which PARP inhibitor?	Johann S. de Bono	10 min
How to manage side effects of PARPi?	Elena Castro	10 min

Q&A (15 min)

Discussion of APCCC 2024 voting results (30 min)

16:00–16:30

Coffee break

16:30–18:15

Session 6

Prostate cancer in low and middle income countries – preparing for the surge in cases	Chairs: Nicholas D. James and Omolara A. Fatiregun	105 min
Lancet Commission on Prostate Cancer– the forthcoming surge in prostate cancer raises very different issues to the ones we face today	Nicholas D. James	8 min
How do we maximise use of radiotherapy for prostate cancer in Africa	Omolara A. Fatiregun	8 min

# Friday, April 26

How do we modify the diagnostic pathway to deal with rising rates of prostate cancer in Africa?	Onyeunam N. Ekeke	8 min
Dealing with inequality 1 - what can we learn from the Indian healthcare system	Vedang Murthy	8 min
Dealing with inequality 2 - the promise and pitfalls for social media and AI for prostate cancer in disadvantaged populations	Stacy Loeb	8 min
Dealing with inequality 3 - what can we learn from the Brazilian Unified Healthcare system (SUS) - opportunities for big data mining and system remodelling	Fernando C. Maluf	8 min
How to deal with the projected rise of prostate cancer cases in the Chinese healthcare system	Dingwei Ye	8 min

Q&A (15 min)

Panel Discussion: Conclusions, possible solutions and next steps

Mouna Ayadi, Omolara A. Fatiregun, Fernando C. Maluf, Vedang Murthy, James N'Dow, Dingwei Ye and Franco Cavalli with WHO representative André Ilbawi (30 min)

18:15

End of Day 2



# Saturday, April 27

09:00-10:15

## Session 7

Advanced Prostate Cancer	Chairs: Himisha Beltran and Andrew J. Armstrong	75 min
Who should undergo germline testing?	Heather H. Cheng	10 min
How do non-DDR genomic alterations influence management of patients with advanced prostate cancer?	Ana Aparicio	10 min
How to identify aggressive variant prostate cancer	Himisha Beltran	10 min
How to treat aggressive variant prostate cancer	Andrew J. Armstrong	12 min
Q&A (15 min)		
Discussion of APCCC 2024 voting results (15 min)		

10:15-10:30

## Coffee break

10:30-12:15

## Session 8

PSMA for Diagnostics and Treatment	Chairs: Louise Emmett and Matthew R. Smith	105 min
PSMA radioligand therapy – state of the art	Ken Herrmann	10 min
Patient selection for radioligand therapy: How to do it in clinical practice and how to decide on the number of cycles	Thomas A. Hope	10 min
Dosing of radioligand therapy in special situations and/or toxicity	Louise Emmett	10 min
Who should receive chemotherapy before PSMA radioligand therapy?	Matthew R. Smith	10 min
Alternative PSMA ligands for diagnostics and treatment – Are they interchangeable?	Michael S. Hofman	10 min
How to utilize presence or absence of CT findings on a PSMA PET/CT?	Stefano Fanti	10 min
Q&A (15 min)		
Discussion of APCCC 2024 voting results (30 min)		

12:15

## Closing Remarks: Silke Gillissen and Aurelius Omlin